Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828910 | 1.00 | PARP1 (0.58) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL17068124 | 1.00 | PARP1 (0.58) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6334954 | 0.96 | PARP1 (0.63) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL2420439 | 0.96 | PARP1 (0.63) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL20129602 | 0.96 | PARP1 (0.63) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL22034240 | 0.94 | PARP1 (0.54) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL7496827 | 0.91 | PARP1 (0.56) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL7494554 | 0.91 | PARP1 (0.56) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL19959259 | 0.91 | PARP1 (0.58) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL21594462 | 0.91 | PARP1 (0.63) | PARP1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4480482-A2 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | AbbVie Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | ABBVIE INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4249073-B1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240109877-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4327814-A2 | MORPHOLINYL, PIPERAZINYL, OXAZEPANYL AND DIAZEPANYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4294800-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117083274-A | Fused ring heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023183811-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003041711-A1 | PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-22 | — | — | WO | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1194152-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1194152-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6316444-B1 | SRC kinase inhibitor compounds | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000214-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | PARP1 404/4885PDK1 1176/4885PDK2 725/4885 |
| US-20240109877-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | PARP1 404/4885PDK1 1176/4885PDK2 725/4885 |
| US-12319679-B2 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MAN2A1, MAN2B2, MGAT3 | PARP1 3527/4885PDK1 1670/4885PDK2 1099/4885 |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | BTK, TYMP, LYN | PARP1 404/4885PDK1 1176/4885PDK2 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.